Drugs / BNT321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06069778 | Mar → Sep 2024 | malignant pancreatic neoplasm | BioNTech SE | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-11-14 | BioNTech SE | Regulatory BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results biontech.com ↗
Successfully transferred IND for BNT321 to BioNTech. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-11-14 | BioNTech SE | BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06069778 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06069778 ↗ |